Immunotherapy for Gastroesophageal Cancer
AbstractSurvival for patients with advanced oesophageal and stomach cancer is poor; together these cancers are responsible for more than a million deaths per year globally. As chemotherapy and targeted therapies such as trastuzumab and ramucirumab result in modest improvements in survival but not long-term cure for such patients, development of alternative treatment approaches is warranted. Novel immunotherapy drugs such as checkpoint inhibitors have been paradigm changing in melanoma, non-small cell lung cancer and urothelial cancers. In this review, we assess the early evidence for efficacy of immunotherapy in patients with gastroesophageal cancer in addition to considering biomarkers associated with response to these treatments. Early results of Anti- Programmed Cell Death Protein-1 (anti-PD-1), anti-PD-L1 and anti-Cytotoxic T-lymphocyte assosciated protein-4 (anti-CTLA4) trials are examined, and we conclude with a discussion on the future direction for immunotherapy for gastroesophageal cancer patients. View Full-Text
Share & Cite This Article
Goode, E.F.; Smyth, E.C. Immunotherapy for Gastroesophageal Cancer. J. Clin. Med. 2016, 5, 84.
Goode EF, Smyth EC. Immunotherapy for Gastroesophageal Cancer. Journal of Clinical Medicine. 2016; 5(10):84.Chicago/Turabian Style
Goode, Emily F.; Smyth, Elizabeth C. 2016. "Immunotherapy for Gastroesophageal Cancer." J. Clin. Med. 5, no. 10: 84.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.